Efficacy of Statin Therapy in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis
Open accessThe DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index.
Abstract
Since the evidence regarding statin therapy in PAH has not been conclusive, we assessed the impact of statin therapy in PAH through a systematic review and meta-analysis of available studies. We searched selected databases up to August 1, 2015 to identify the studies investigating the effect of statin administration on PAH. Meta-analysis was performed using either a fixed-effects or random-effect model according to I2 statistic. Meta-analysis of 8 studies with 665 patients did not suggest any significant improvement in 6-min walking distance (6MWD) by statin therapy (weighed mean difference [WMD]: −6.08 m, 95% confidence interval [CI]: −25.66, 13.50, p = 0.543; Q = 8.41, I 2 = 28.64%). Likewise, none of the other indices including pulmonary arterial pressure (WMD: −0.97 mmHg, 95%CI: −4.39, 2.44, p = 0.577; Q = 14.64, I 2 = 79.51%), right atrial pressure (WMD: 1.01 mmHg, 95%CI: −0.93, 2.96, p = 0.307; Q = 44.88, I 2 = 95.54%), cardiac index (WMD: 0.05 L/min/m 2, 95%CI: −0.05, 0.15, p = 0.323; Q = 3.82, I 2 = 21.42%), and pulmonary vascular resistance (WMD: −1.42 dyn*s/cm 5, 95%CI: −72.11, 69.27, p = 0.969; Q = 0.69, I 2 = 0%) was significantly altered by statin therapy. In conclusion, the results of the meta-analysis did not show a statistically significant effect of statin therapy in the improvement of 6MWD, pulmonary arterial pressure, right atrial pressure, cardiac index and pulmonary vascular resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Duval, S., & Tweedie, R. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00455.x · Cited by 14,099
Wan, X., Wang, W., Liu, J., & Tong, T. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-135 · Cited by 11,735 · cited 1×
“If the outcome measures were reported in median and range or 95% CI, mean and standard SD values were estimated using the method described by Wan et al.14.”
Method2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv317 · Cited by 6,931
Self-citation(2000) · Queen Mary Research Online (Queen Mary University of London) · Cited by 1,795
Simvastatin Inhibits Cigarette Smoking–induced Emphysema and Pulmonary Hypertension in Rat Lungs
Lee, J.-H., Lee, D.-S., Kim, E.-K., Choe, K.-H., Oh, Y.-M., Shim, T.-S., Kim, S.-E., Lee, Y.-S., & Lee, S.-D. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200501-041oc · Cited by 257
Pharmacologic Therapy for Pulmonary Arterial Hypertension in Adults
Taichman, D. B., Ornelas, J., Chung, L., Klinger, J. R., Lewis, S., Mandel, J., Palevsky, H. I., Rich, S., Sood, N., Rosenzweig, E. B., et al. (2014) · Chest · doi:10.1378/chest.14-0793 · Cited by 256
Nishimura, T., Vaszar, L. T., Faul, J. L., Zhao, G., Berry, G. J., Shi, L., Qiu, D., Benson, G., Pearl, R. G., & Kao, P. N. (2003) · Circulation · doi:10.1161/01.cir.0000087592.47401.37 · Cited by 251
Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group, Banach, M., Serban, C., Sahebkar, A., Mikhailidis, D. P., Ursoniu, S., Ray, K. K., Rysz, J., Toth, P. P., Muntner, P., et al. (2015) · BMC Medicine · doi:10.1186/s12916-015-0459-4 · Cited by 217
Self-citation
Research works printed but not linked: 2
- Galiè, N. et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 37, 67–119 (2016). · DOI · Paper page
- Faul, J. et al. In Pulmonary Hypertension Contemporary Cardiology™ (eds NicholasS Hill & HarrisonW Farber ) Ch. 15, 321–336 (Humana Press, 2008).
Cited by
Xu, Z., Henderson, R. D., David, M., & McCombe, P. A. (2016) · PLOS ONE · doi:10.1371/journal.pone.0164625 · Cited by 115
Wang, D., Uhrín, P., Mocan, A., Waltenberger, B., Breuss, J. M., Tewari, D., Mihaly‐Bison, J., Huminiecki, Ł., Starzyński, R. R., Tzvetkov, N. T., et al. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.04.006 · Cited by 116
Haber, N., Smith, E. R., Moscoe, E., Andrews, K., Audy, R., Bell, W., Brennan, A. T., Breskin, A., Kane, J. C., Karra, M., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0196346 · Cited by 97
“An example in the UK [3] highlights the dangers of weak and poorly-reported evidence: An estimated 200,000 patients temporarily ceased taking statins–drugs with strong evidence for efficacy and safety for treating hypertension [4, 5]–after press outlets reported on two studies suggesting that the medication was associ…”
BackgroundNeurofilament light chain as a biological marker for multiple sclerosis: a meta-analysis study
Cai, L., & Huang, J. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s173280 · Cited by 76
Interplay of Low-Density Lipoprotein Receptors, LRPs, and Lipoproteins in Pulmonary Hypertension
Calvier, L., Herz, J., & Hansmann, G. (2022) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2021.09.011 · Cited by 84
“However, recent published clinical trials and systematic reviews assessing the potential of statins in PH patients are controversial (48,50,144,149) and statins as an effective treatment in PH is still under debate.”
BackgroundResultInfluentialChen, W., Chen, C.-H., Hsu, M., Chang, R.-W., Wang, C., & Lee, T. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116192 · Cited by 86
The effect of statins on psoriasis severity: a meta-analysis of randomized clinical trials
Socha, M., Pietrzak, A., Grywalska, E., Pietrzak, D., Matosiuk, D., Kiciński, P., & Rolinski, J. (2020) · Archives of Medical Science · doi:10.5114/aoms.2019.90343 · Cited by 59
“The results of selected meta-analyses indicate no significant effect of statin therapy on pulmonary arterial hypertension and blood pressure in normotensive and hypertensive subjects [28, 29].”
Dietary natural products as emerging lipoprotein(a)‐lowering agents
Momtazi‐Borojeni, A. A., Katsiki, N., Pirro, M., Banach, M., Al‐Rasadi, K., & Sahebkar, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28134 · Cited by 49
Self-citationConverging Paths of Pulmonary Arterial Hypertension and Cellular Senescence
van der Feen, D. E., Berger, R. M. F., & Bartelds, B. (2019) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2018-0329tr · Cited by 40
Low-density lipoprotein cholesterol and survival in pulmonary arterial hypertension
Kopeć, G., Waligóra, M., Tyrka, A., Jonas, K., Pencina, M. J., Zdrojewski, T. R., Moertl, D., Stokwiszewski, J., Zagożdżon, P., & Podolec, P. S. (2017) · Scientific Reports · doi:10.1038/srep41650 · Cited by 39
Jonas, K., Waligóra, M., Magoń, W., Zdrojewski, T. R., Stokwiszewski, J., Płazak, W., Podolec, P. S., & Kopeć, G. (2018) · Archives of Medical Science · doi:10.5114/aoms.2018.79242 · Cited by 33
Ferretti, G., Bacchetti, T., Banach, M., Simental‐Mendía, L. E., & Sahebkar, A. (2017) · Angiology · doi:10.1177/0003319716688301 · Cited by 32
Self-citationWong, M. J., Kantores, C., Ivanovska, J., Jain, A., & Jankov, R. P. (2016) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00345.2016 · Cited by 29
“Despite favorable results in adult experimental chronic PHT (21, 44, 52, 63), trials employing statins in human adults with chronic PHT have thus far shown an apparent lack of efficacy (57).”
Zhang, B., Naik, J. S., Jernigan, N. L., Walker, B. R., & Resta, T. C. (2017) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00540.2017 · Cited by 26
Statins may be beneficial for patients with pulmonary hypertension secondary to lung diseases
Zhang, M., Qian, D., Xu, J., Yao, W., Ye, F., & Wang, C. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.07.06 · Cited by 19
“Several observational studies have reported attenuation of PAH progression by statins, however, published meta-analysis of randomized trials demonstrated that statins may not be useful as a specific treatment for this disease (32-36).”
BackgroundRabacal, W., Schweitzer, F., Rayens, E. A., Tarantelli, R., Whang, P., Jiménez, V. C., Outwater, J. A., & Norris, K. A. (2019) · Scientific Reports · doi:10.1038/s41598-019-55301-9 · Cited by 15
Farahmand, F., Malik, A., Sharma, A. K., Bagchi, A. K., & Singal, P. K. (2021) · Physiological Reports · doi:10.14814/phy2.15090 · Cited by 13
Are statins beneficial for the treatment of pulmonary hypertension?
Wang, L., Yang, T., & Wang, C. (2017) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2017.10.001 · Cited by 12
“The other meta-analysis, which included eight studies comprising 665 patients, showed no improvement in many clinical indices, such as 6MWD, pulmonary arterial pressure, right atrial pressure, cardiac index, and pulmonary vascular resistance, in patients treated with statins.(79) In 2017, Zhang et al(80) reviewed six…”
ResultA Systematic Review of Novel Therapies of Pulmonary Arterial Hypertension
Nabeh, O. A., Saud, A. I., Amin, B., Khedr, A. S., Amr, A., Faoosa, A. M., Esmat, E., Magdy, Y., Hatem, A. M., Mohamed, M., et al. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00613-5 · Cited by 9
“Preliminary studies for statins did not show significant improvement in PAH patients [4], and rodatristat, olapa-rib, and endothelin progenitor cell investigations are still ongoing and their results are awaited.”
BackgroundChen, F., Yang, M. X., Wan, C., Liu, L., & Chen, L. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.11.19 · Cited by 9
“Some meta-analyses showed that statins treatment had no effect of PAP in PH patients (11-13).”
BackgroundSugimoto, K., Yokokawa, T., Misaka, T., Kaneshiro, T., Yoshihisa, A., Nakazato, K., & Takeishi, Y. (2021) · BMC Cardiovascular Disorders · doi:10.1186/s12872-021-02143-x · Cited by 3
Muhammad, R. N., Aborehab, N. M., Aly, S. H., Nasr, N. N., Hindam, M. O., Mustafa, A. M., Faheem, S. A., Fawzy, M. H., Fetoh, M. E. A., El‐Dessouki, A. M., et al. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-02069-2 · Cited by 6
“Statins improve the condition of the endothelium and enhance the bioavailability of NO; both of these mechanisms play a role in reducing vascular inflammation and pulmonary hypertension, which typically occur in the respiratory complications (Rysz-Górzynska et al. 2016).”
Xu, G., Zhang, R., Huang, W., Du, X., & Xu, W. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1640270 · Cited by 2
Krása, K., Vajnerová, O., Ďurišová, J., Minaříková, M., Miková, D., Srbová, M., Chalupský, K., Kaftanová, B., & Hampl, V. (2022) · Physiological Research · doi:10.33549/physiolres.934913 · Cited by 2
When higher cholesterol is better: membrane cholesterol loss and endothelial Ca2+ signaling
Huetsch, J., Suresh, K. S., & Shimoda, L. A. (2017) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00655.2017 · Cited by 2
“, reducing vasoconstriction via inhibition of Rho kinase), testing the effect of this drug on PAEC Ca(2) entry would be of interest given equivocal effects of statin therapy in patients (2, 22, 29, 34).”
Kar, T. A., Qadri, S. M., Altaf, J., Wani, A. A., Hamid, S., Hamid, I., Khan, U. H., & Hafeez, I. (2025) · Cureus · doi:10.7759/cureus.89985 · Cited by 2
“…pressure (PASP) as a marker of pulmonary hypertension severity, RV dimensions, and tricuspid annular plane systolic excursion (TAPSE) as key indicators of right ventricular size and contractile performance, and left ventricular (LV) diastolic indices to detect subclinical cardiac dysfunction [4].”
Baseri, S., Izadi, M., Alimohammadi, M., Khoshnazar, S. M., Nikdel, R., & Hushmandi, K. (2026) · European journal of medical research · doi:10.1186/s40001-025-03782-y · Cited by 4
“These findings support and expand on previous evidence of statins’ pleiotropic effects in pulmonary disease modulation [41].”
Rose, J., Chang, T., Nghiem, T., Shah, A., Shaikh, R., Gardner, M., Ali, K., Oliveira, S. D. D., & Alfaidi, M. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1733624 · Cited by 1
Oxidative Stress in Pulmonary Artery Hypertension
Wilson, V., & Maulik, S. K. (2019) · Springer eBooks · doi:10.1007/978-981-13-8946-7_16
Taran, I. N., Архипова, О. А., Масенко, В. П., Борисович, Д. А., & Martynyuk, T. V. (2019) · PULMONOLOGIYA · doi:10.18093/0869-0189-2019-29-2-175-183
Lipid‐Lowering Drugs and Pulmonary Vascular Disease: A Mendelian Randomization Study
Yuan, X., Hong, P., & Zhou, J. (2025) · Pulmonary Circulation · doi:10.1002/pul2.70043
Sugimoto, K., Yokokawa, T., Misaka, T., Kaneshiro, T., Yoshihisa, A., Nakazato, K., & Takeishi, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14920920
Csonka, D., Gargano, C., Goyal, N., Meulder, M. D., Yartsev, V., & Ruixo, J. J. P. (2026) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.70185
“23 Pre-clinical, in vitro studies suggest potential interactions between macitentan and substrates of both breast cancer resistance protein (BCRP) transporter (e.g., riociguat and rosuvastatin), as well as cytochrome P450 3A4 (CYP3A4) enzymes (e.g., sildenafil and tadalafil).”
Metadata
- Authors
- Rysz-Górzynska, M., Gluba-Brzózka, A., Sahebkar, A., Serban, M.-C., Mikhailidis, D. P., Ursoniu, S., Toth, P. P., Bittner, V., Watts, G. F., Lip, G. Y. H., Rysz, J., Catapano, A. L., & Banach, M.
- Affiliations
- Medical University of Lodz (PL)
- Mashhad University of Medical Sciences (IR)
- The Royal Free Hospital (GB)
- Victor Babeș University of Medicine and Pharmacy Timișoara (RO)
- Johns Hopkins Medicine (US)
- University of Alabama at Birmingham (US)
- The University of Western Australia (AU)
- Birmingham City Hospital (GB)
- University of Milan (IT)
- Corresponding author
- Banach, Maciej
- ORCID
- Venue
- Scientific Reports
- Published
- 2016-07-22
- Volume
- 6
- Issue
- 1
- Pages
- 30060-30060
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC4957081
- OpenAlex
- W2495160769
- Cited by
- 33
- References
- 52
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 1 · 2023: 1 · 2022: 2 · 2021: 3 · 2020: 1 · 2019: 6 · 2018: 4 · 2017: 6 · 2016: 2
- FWCI
- 1.04
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- UWA Profiles and Research Repository (UWA) (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Funders
- Uniwersytet Łódzki (REGPOT-2012-2013-1)
- FP7 Research Potential of Convergence Regions (REGPOT-2012-2013-1)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- statin therapy, pulmonary arterial hypertension, 6-minute walk distance, pulmonary vascular resistance, right atrial pressure, cardiac index, pulmonary artery pressure, exercise capacity
- MeSH terms
- Female, Humans, Hypertension, Pulmonary, Male, Vascular Resistance, Treatment Outcome, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Atrial Pressure, Arterial Pressure
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.